Investigating a new treatment for glioblastoma using a novel drug.
6-thio-2'-deoxyguanosine in GBM: Evaluation of Pharmaco-dynamics, Effects of Prior Standard of Care and A Human Phase 0 Study
This study is looking at a new drug that might help fight glioblastoma, a tough type of brain cancer, by targeting cancer cells and boosting the immune system, and it offers patients a chance to be part of early trials that could lead to better treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10919214 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma, a highly aggressive brain tumor with poor survival rates. The team will explore a new drug called 6-thio-2'-deoxyguanosine, which targets telomerase in cancer cells, potentially leading to cell death and activating the immune system against the tumor. The study includes pre-clinical models and a Phase 0 clinical trial to assess how well this drug works in humans and to identify biomarkers that predict response to treatment. Patients may have the opportunity to participate in early trials that could pave the way for new therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who have been diagnosed with glioblastoma.
Not a fit: Patients with glioblastoma who have already exhausted all treatment options or those with other types of brain tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, improving survival rates and quality of life for patients.
How similar studies have performed: While the approach of using telomerase-targeted therapies is promising, this specific application of 6-thio-2'-deoxyguanosine in glioblastoma is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Khasraw, Mustafa — Duke University
- Study coordinator: Khasraw, Mustafa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.